In addition, future studies involving the use of other ccRCC cell lines with VHL mutations are warranted not only to validate our results but to also elucidate the molecular mechanisms underlying SGLT2-mediated ccRCC progression. The gene discussed is VHL; the disease is nonpapillary renal cell carcinoma.